kathimerini.gr

SGLT-2 Inhibitors Added to Heart Failure Treatment Guidelines

New guidelines recommend SGLT-2 inhibitors for heart failure patients, improving outcomes and reducing hospitalizations; studies show reduced death and hospitalization risks compared to standard care; this is due to their diuretic effects and positive impact on kidney function, thus benefiting both the heart and kidneys.

Read original article in Greek

Greek

Greece

HealthScienceHealthcareMedical ResearchHeart FailureCardiologySglt-2 InhibitorsTreatment Guidelines

American College Of CardiologyAmerican Heart Association

Deepak L. Bhatt

How do SGLT-2 inhibitors impact heart failure patients, and what evidence supports their efficacy?: The addition of SGLT-2 inhibitors to heart failure treatment significantly alters the therapeutic landscape. Studies published in The New England Journal of Medicine (October 14, 2021) and The Lancet (September 19, 2020) demonstrate reduced risks of death and hospitalization in patients with both HFrEF and HFpEF who received SGLT-2 inhibitors, compared to those receiving standard care. This improvement is attributed to SGLT-2 inhibitors' diuretic effect, sodium level reduction, and weight loss benefits, alongside their positive impact on kidney function.
What is the immediate clinical significance of adding SGLT-2 inhibitors to heart failure treatment guidelines?: Approximately 6.2 million adults in the US suffer from heart failure, and hospitalizations due to this disease have increased in recent years. New guidelines from April 2022 recommend SGLT-2 inhibitors, a class of antidiabetic agents, as an additional treatment option for heart failure patients, regardless of diabetes status, leading to reduced complications and hospitalizations.
What are the potential long-term effects of widespread SGLT-2 inhibitor adoption on heart failure management and healthcare systems?: The long-term impact of incorporating SGLT-2 inhibitors into standard heart failure treatment will likely involve a decrease in hospital readmissions and improved patient survival rates. Further research could investigate the optimal combination of SGLT-2 inhibitors with existing medications to maximize therapeutic benefits, and also explore the potential for preventative use of SGLT-2 inhibitors in high-risk individuals to reduce incidence of heart failure.

Cognitive Concepts

2/5

Framing Bias

The article's framing is largely positive towards SGLT-2 inhibitors, emphasizing their benefits and presenting them as a breakthrough in heart failure treatment. The headline (if any) and introduction likely contribute to this positive framing by highlighting the new treatment option's potential impact. While this is understandable given the nature of the new treatment, a more balanced perspective acknowledging existing treatments and their efficacy would improve neutrality.

1/5

Language Bias

The article uses language that is generally neutral and informative, however, phrases like "game-changer" and "breakthrough" when describing the new medication might be considered slightly loaded, conveying more enthusiasm than strictly objective reporting. More neutral alternatives could be 'significant development' or 'important addition to treatment options'.

3/5

Bias by Omission

The article focuses heavily on the benefits of SGLT-2 inhibitors for heart failure, but doesn't discuss potential drawbacks or limitations in detail. While it mentions potential side effects like genital yeast infections, a more comprehensive discussion of risks, contraindications, or potential interactions with other medications would provide a more balanced perspective. The article also omits discussion of the cost of these medications and their accessibility to different populations.

1/5

False Dichotomy

The article doesn't present a false dichotomy, but it could benefit from acknowledging the complexity of heart failure treatment. While SGLT-2 inhibitors are presented as a significant advancement, the article could mention that they are not a cure and that individual responses to treatment vary.

Sustainable Development Goals

Good Health and Well-being Positive

Direct Relevance

The article discusses new guidelines that include SGLT-2 inhibitors for treating heart failure, leading to reduced complications, hospitalizations, and increased lifespan. This directly improves cardiovascular health and overall well-being.

Jun 11, 04:11

Sensory Changes: Early Warning Signs of Dementia

Experts warn that changes in sight, hearing, taste, touch, and balance can be early signs of dementia, striking years before memory problems, offering hope for earlier diagnosis and intervention; studies show sensory changes are often overlooked, highlighting the need for their inclusion in standard diagnostic tests.

Jun 11, 10:14

China Approves Novel Influenza Drug Onradivir

China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance than existing drugs; it's administered as a 0.6-gram tablet three times daily for five days.

Jun 11, 10:14

China Approves Novel Influenza Drug Onradivir

China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance potential than existing drugs like oseltamivir and baloxavir marboxil, potentially reducing the global burden of influenza.

Jun 10, 01:11

Appendiceal Cancer Rates Surge Among Millennials

A Vanderbilt University study reveals a sharp increase in appendiceal cancer among Millennials, with rates seven times higher in their 30s than in the 1940s, possibly due to a new environmental exposure; early diagnosis significantly improves survival.